Abstract
Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizers, we conducted a high-throughput screen of therapeutic agents and identified the PARP-1 inhibitor, talazoparib, as a top hit. Mechanistically, RT3D activates PARP-1 via RIG-I, leading to the PARylation of extrinsic apoptosis pathway components that act as a "brake" on cell death. Pharmacological inhibition of PARP-1 with talazoparib abrogates this brake, enhancing apoptosis and pro-inflammatory signaling. In vivo, this combination induces complete tumor control and long-term immune memory, protecting mice from subsequent tumor rechallenge.
Introduction
Oncolytic viruses (OVs) are designed to selectively infect and destroy cancer cells. While promising, their clinical efficacy as monotherapies is often limited by tumor resistance and rapid viral clearance. To overcome these barriers, researchers seek "sensitizers"—drugs that can amplify the viral effect. This study identifies talazoparib, a PARP inhibitor (PARPi), as a potent sensitizer for Reovirus type 3 Dearing (RT3D), revealing a novel non-canonical role for PARP-1 in viral-induced cell death.
Methods and Experimental Design
The researchers utilized an unbiased high-throughput screen of 80 therapeutic agents to identify sensitizers in melanoma cell lines. Following the identification of talazoparib, the team employed:
- Proteomics: TMT-11plex mass spectrometry to map signaling pathways.
- Genetic Validation: CRISPR-Cas9 to knockout PARP-1, confirming its role as the primary mediator.
- Biochemical Assays: Immunoprecipitation and PARP-trap assays to observe the RIG-I/dsRNA/PARP-1 complex.
- In Vivo Models: Syngeneic mouse models (4434 melanoma) were used to evaluate tumor control and immune memory.
Key Insights: A Non-Canonical Mechanism
The synergy between talazoparib and RT3D does not depend on the classic "synthetic lethality" associated with DNA repair defects (e.g., BRCA mutations). Instead, it involves a novel immune-signaling pathway:
- The Brake: RT3D infection triggers the RIG-I sensor, which recruits PARP-1. PARP-1 then PARylates the cell's death machinery (the DISC complex), preventing rapid apoptosis and allowing the tumor to survive.
- The Release: Talazoparib inhibits PARP-1 and "traps" it on the RIG-I/dsRNA complex. This prevents the inhibitory PARylation, flipping the switch from survival to pro-inflammatory cell death.
- Positive Feedback: This process activates IFN-β and TNF/TRAIL production, further amplifying the therapeutic effect.
Results
Potent In Vitro Synergy
Talazoparib demonstrated "supra-additive" cell killing across multiple melanoma and breast cancer cell lines. The effect was dose-dependent, with even low concentrations of talazoparib significantly lowering the threshold for viral-induced death.
Complete Tumor Control and Immune Memory
In immunocompetent mouse models, the combination of RT3D and talazoparib achieved a 100% cure rate (6/6 mice). Beyond initial clearance, the treatment acted as an in situ vaccine. Mice that were successfully cured rejected a second injection of the same tumor cells months later, indicating the development of robust, long-term adaptive immune memory.
Discussion and Future Directions
This study highlights a powerful new strategy for enhancing oncolytic virotherapy. By repurposing PARP inhibitors to target viral sensing pathways rather than DNA repair, the scope of PARPi therapy could be expanded to a broader range of cancers.
However, challenges remain for clinical translation. Optimal dosing schedules must be established to balance efficacy and toxicity. Furthermore, the observation that the treatment upregulates PD-L1 suggests that combining this regimen with immune checkpoint inhibitors (anti-PD-1/PD-L1) could further enhance its potency, particularly in "cold" or resistant tumors.
Summary updated